Welcome to www.angiodynamics.com, AngioDynamics' United States web site (the Site).
Content. AngioDynamics will use reasonable efforts to include up-to-date and accurate information in this Site, but makes no representations, warranties, or assurances as to the accuracy, currency or completeness of the information provided. You agree that access to and use of this Site and the content hereof is at your own risk. All information on this Site is provided "AS IS." WITHOUT LIMITING ANY OF THE TERMS OF THIS AGREEMENT, IN NO CASE SHALL ANGIODYNAMICS BE LIABLE IN RESPECT OF THE INFORMATION ON THIS SITE OR ANY USE THEREOF, FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES BASED UPON BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY, OR ANY OTHER LEGAL THEORY. THESE TERMS MAY NOT BE ALTERED, AMENDED, REPLACED, SUBSTITUTED OR RESCINDED BY ANY EMPLOYEE, AGENT, INDEPENDENT CONTRACTOR OR CONSULTANT OF ANGIODYNAMICS. ANY SUCH ALTERATION, AMENDMENT, REPLACEMENT, SUBSTITUTION OR RESCISSION SHALL NOT BE BINDING UPON ANGIODYNAMICS OR ITS AFFILIATES. AngioDynamics also assumes no responsibility, and shall not be liable for, any damages to, or viruses that may infect, your computer equipment or other property on account of your access to, use of, browsing in the Site, or your downloading of any materials, data, text, images, video, or audio from the Site.
Copyrights and Trademarks. AngioDynamics, the AngioDynamics logo, Navilyst Medical, the Navilyst Medical logo, Abscession, Acceler-8, Accu-Vu, Acculis, Angioflush, AngioOptic, Angio-Sac, AngioVac, Avenue, Benephit, BioFlo, the BioFlo seal, Blue Silk, Charter, Circle C, Compensator, Crystaline, Curved Tip, DuraFlow, DuraMax, Durathane, Duration, Dynamic-Flow, EMBARC, Embosafe, Engineered for Excellence, Engineered for Life, Essentials, Evenmore, EVLT, Exact-Length, EXODUS, FLEXCIL, Flow-Thru Hub, Fluoromax, Glyce, Hemo-Lock, Hydro-Tip, Infuse-A-Port, Intelliflow, LifeGuard, LifeJet, LifePort, LifeValve, Mariner, Maximizing VenaCure Potential, Mini Stick, Mini Stick II, Morpheus, MORSE, NAMIC, NanoBurst, NanoKnife, the NanoKnife logo, , NanoRay, NeoStar, NeverTouch, NeverTouch Direct, Nit Vu, Omni, One Step, Optiguide, Option 125, PASV, PeelPro, PERCEPTOR, Precision 980, PRO, Profiler, Protection Station, Pulse Spray, QuickStic, Rita, Saver-7, Sheath-Lok, Smart, Smart Angle, Smart Port, Smart Taper, Snap-Lock, Soft-Vu, SOS Omni, SOSA, SpeedLyser, Spotlight OPS, Squeeze Contrast Controller, StarBurst, Super-Radiopaque, Sulis, TD2, The Greatest Experience in Eliminating Varicose Veins, The Grip, The Power of PASV, Thermopad, TitanPort, Tre-Sheath, Triumph-1, Uni*fuse, Uniblate, VascPak, Vault, VAXCEL, VenaCure, VenaCure EVLT, the VenaCure logo, the VenaCure EVLT logo, VIP VenaCure in Practice, VOLTA, Vortex, Workhorse and XCELA are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. All of the trademarks, service marks and logos displayed on this Site are registered and unregistered trademarks of AngioDynamics, its affiliates or subsidiaries, or third parties who have licensed their trademarks to AngioDynamics or one of its affiliates or subsidiaries. In addition, all content, including but not limited to text, software, music, sound, photographs, video, graphics or other material contained on this Site or in commercially produced information presented to you through the Site by AngioDynamics, its affiliates or AngioDynamics' third party licensors (Content) is protected by copyright, patents or other proprietary agreements and laws and you are only permitted to use Content as expressly authorized by AngioDynamics, its affiliates or its licensors. Nothing contained herein transfers any right, title, or interest in the Site or the Content to you.
Medical Information. The information provided by this Site is not intended nor is implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health care provider prior to starting any new treatment or with any questions you may have regarding a medical condition. We may also include certain information, reference guides and databases intended for use by licensed medical professionals. These tools are not intended to give professional medical advice. Physicians and other health care providers should always exercise their own clinical judgment for any given situation.
Physicians. AngioDynamics may, through this Site, assist you in searching for or identifying a physician or clinic in your area able to treat a certain condition. In such cases, we do not have any ownership or direct financial interest in any of the specific physicians or clinics listed and do not endorse, certify or recommend any of these physicians or clinics. We do not guarantee or makes any warranties, express or implied, as to the quality of medical advice or care given by any physician or clinic.
Availability of Products. AngioDynamics' products referred to on this Site may not be available for sale in all countries. We make no representation as to the availability of a particular product in a particular country. For the availability of a particular product in your country, please contact us.
Forward Looking Statements. This Site includes "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "estimate," "seek," "continue," "pursue," or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular, they include statements relating to, among other things, future actions, strategies, future performance and future financial results of AngioDynamics. These forward-looking statements are based on current expectations and projections about future events.
Investors are cautioned that forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties that cannot be predicted or quantified and, consequently, the actual performance or results of AngioDynamics may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the factors described from time to time our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2009, financial community and rating agency perceptions of AngioDynamics; the effects of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; domestic and foreign health care reforms and governmental laws and regulations; third-party relations and approvals, technological advances and patents attained by competitors; and challenges inherent in new product development, including obtaining regulatory approvals. In addition to the matters described above, our ability to develop products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the outcome of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, and the effects on pricing from group purchasing organizations and competition and our ability to integrate purchased businesses, may affect the actual results achieved by AngioDynamics.
Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated.
Export Restrictions/Legal Compliance. AngioDynamics administers and controls this Site from within the United States of America. You may not access, download, use or export the Site or its content in violation of U.S. export laws or regulations, or in violation of any other applicable laws or regulations.
No Reproduction of the Site. Your right to use the Site is personal to you. You agree not to reproduce, duplicate, copy, sell or resell the Site, without the express written consent of AngioDynamics.
Indemnity. You agree to indemnify, defend and hold AngioDynamics, its subsidiaries, affiliates, shareholders, directors, officers, employees and agents, harmless from any claim, demand, liability, expense, or loss, including reasonable attorneys' fees, made by any third party due to or arising out of, or in any way connected with your use of or access to the Site or your violation of these Terms.
AngioDynamics Reports 2014 Fourth Quarter and Full Year Financial Results
- Fourth Quarter of Fiscal 2014 Net sales increased 4% to $94.1 million; Average Daily Sales grew 7%, excluding supply agreement
- Q4 FY14 GAAP loss of $0.03 per share; Non-GAAP adjusted net income, excluding amortization, of $0.18 per share
- Q4 FY14 Operating cash flow of $10.1 million
- Company introduces financial guidance for FY2015
ALBANY, N.Y., July 23, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the fourth quarter and fiscal year ended May 31, 2014.
"The strong top-line performance generated throughout fiscal year 2014 continued in the fourth quarter. We experienced a 7% increase in Average Daily Sales (ADS), excluding revenue from the Boston Scientific agreement, driving us to a fifth consecutive quarter of improved sales results," said Joseph M. DeVivo, President and Chief Executive Officer. "Capping off a very successful year for AngioDynamics, this strong sales performance was driven by our key growth drivers, including the BioFlo family of products in our Vascular Access business, AngioVac cannula and circuit in our Peripheral Vascular business and Acculis microwave system in our Oncology/Surgery business. All three of our businesses posted year-over-year growth for the second consecutive quarter, and we are particularly pleased with the continued turnaround in Vascular Access, which grew 5% over last year as more customers are realizing the clinical benefits of our disruptive BioFlo technology.
"Having achieved our goal of mid-single digit annual sales growth for fiscal 2014, we are well positioned for continued strong top-line performance as we enter fiscal 2015," Mr. DeVivo added. "As we progress through fiscal year 2015 we will continue to implement our Operational Excellence plan and expect earnings growth to outpace sales increases."
Q4 FY14 Financial Results
Net sales of $94.1 million were up 4% compared with last year's fourth quarter net sales of $90 million. Excluding the planned wind-down of the supply agreement with Boston Scientific (BSC), fourth quarter sales were up 5% to $92.9 million compared to $88.4 million in last year's fourth quarter. The following sales comparisons exclude the BSC supply agreement.
Peripheral Vascular net sales in the fourth quarter increased 6% to $50.9 million compared to $48 million in the prior year period. Vascular Access net sales increased 5% to $28.3 million compared to $27 million in the year ago quarter. Oncology/Surgery net sales of $13.7 million increased 1% compared to the year ago quarter. Net sales in the U.S. increased 6% to $73.7 million from $69.7 million in the prior year period. International net sales grew 2% to $19.2 million from $18.8 million in last year's fourth quarter.
The Company's net loss in the fourth quarter was $1.1 million, or $0.03 on a per share basis, compared to net loss of $0.9 million, or $0.02 per share, a year ago. During AngioDynamics' fourth quarter of fiscal 2014, the state of New York enacted a reform package eliminating the income tax on qualified New York state manufacturers. As a result, anticipated future benefits from net tax assets were eliminated requiring the Company to record a non-cash charge totaling $1.2 million, or $0.03 per share, during the quarter. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $6.4 million, or $0.18 per share, for the fourth quarter compared to net income of $5.2 million, or $0.15 per share, for the year ago quarter.
Fourth quarter EBITDA grew to $9.9 million, or $0.28 per share, compared to $7.9 million, or $0.22 per share, in the year ago comparable period. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $14.7 million, or $0.41 per share, compared to $13.7 million, or $0.39 per share, in the year ago comparable period.
At May 31, 2014, cash and investments were $17.9 million and debt was $142.7 million.
- Novation awarded AngioDynamics an Innovative Technology Contract covering BioFlo PICC and BioFlo Port products. Unlike other thromboresistant products, the technology behind the Company's disruptive BioFlo devices is designed to be both present throughout the entire catheter and permanent, leading to decreased accumulation of catheter-related thrombus without incorporation of heparin, antibiotics or antimicrobials, or any other transient materials typically associated with coated or impregnated technologies.
- The Company received Certificate to Foreign Governments (CFGs) from the U.S. Food and Drug Administration covering all Vascular Access and Peripheral Vascular products manufactured in its Queensbury facility. CFGs allow for the commercialization of these products in countries that require a U.S. FDA CFG, along with other appropriate regulatory documentation specific to the country.
- AngioDynamics announced FDA clearance for the Celerity tip location system and began shipping to U.S. customers in mid-July 2014. The Celerity System has been cleared by the FDA as an adjunct to aid in positioning Peripherally Inserted Central Catheters (PICCs) in adults by providing real time catheter tip location utilizing the patient's cardiac electrical activity.
- Howard W. Donnelly, President of Concert Medical LLC, was named Chairman of AngioDynamics' Board of Directors.
- Following the completion of its New York Distribution Center of Excellence, AngioDynamics began construction of its New York Manufacturing Center of Excellence, as part of its Operational Excellence program that is expected to save the Organization $15 million to $18 million over the next three years.
- The Company received Premier Inc.'s first Supplier Horizon Award presented at Premier's annual Breakthroughs Conference and Exhibition in San Antonio. The Company was recognized in the Nursing category based on exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs.
Full Year Financial Results
As part of the fiscal year-end financial closing process, the Company identified an immaterial accounting error resulting from the ERP implementation in January 2014. The Company has concluded that this error was not material to its previously issued consolidated financial statements and has revised its previously reported results for the third quarter fiscal 2014 to correct this error. As a result, the Company's fiscal 2014 third quarter financial results were revised downward by $0.7 million incremental pretax cost of sales, or $0.01 per share. Adjusted EPS for the fiscal 2014 third quarter was revised to $0.14 from $0.16. This revision is included in the fiscal 2014 annual financial results and third quarter fiscal 2014 financial results will be adjusted for future presentations of quarterly financial results.
For the full year ended May 31, 2014, net sales were $354.5 million, a 4% increase compared to the $342 million reported a year ago. The Company's net income was $3.1 million, or $0.09 per share, compared to net loss of $0.6 million, or $0.02 per share, reported a year ago. Excluding the items shown in the attached quarterly non-GAAP reconciliation table, adjusted net income was $20.6 million, or $0.58 per share, compared to net income of $22.7 million, or $0.64 per share, a year ago. EBITDA was $38.3 million, or $1.08 per share, compared to $32.3 million, or $0.91 per share, a year ago. Adjusted EBITDA, excluding the items shown in the attached reconciliation table, was $52.2 million, or $1.47 per share, compared to $57 million, or $1.61 per share, in the year ago period.
Fiscal 2015 and First Quarter Guidance
"Building on our improved sales performance throughout 2014, we are guiding to a full fiscal year range of $362 million to $368 million in revenue, reflecting 3-5% growth excluding the impact of the planned wind down of our supply agreement, which we expect to decline by approximately $4 million as compared to fiscal 2014," said Mark Frost, Executive Vice President and Chief Financial Officer. "We anticipate delivering stronger operating leverage in fiscal year 2015 and are guiding to adjusted earnings per share (EPS), of $0.64-$0.70, representing a 10-21% increase over fiscal 2014.
"We anticipate revenue to range from $83 million to $86 million in the first quarter of fiscal 2015, a 4% increase at the top end of the range, excluding the wind-down reduction," Mr. Frost continued. "Adjusted EPS is expected to be in the range of $0.08-$0.12."
AngioDynamics will host a conference call today at 4:30 p.m. Eastern Time to discuss its fourth quarter results. To participate in the live call by telephone, please call 1-888-438-5525 and reference the Conference ID: 2297923. In addition, a live webcast, available slides and archived replay of the call will be available at http://investors.angiodynamics.com. To access the live webcast, please go to the website 15 minutes prior to its start to register, download and install the necessary software.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported net sales, net of a supply agreement; Average Daily Sales (ADS) growth net of a supply agreement, which is calculated as a growth rate of total sales per shipping day as compared to the prior year quarter; EBITDA (income before interest, taxes, depreciation and amortization); adjusted EBITDA; adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics, the AngioDynamics logo, Acculis, AngioVac and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Celerity is a trademark and/or registered trademark of Medical Components Inc.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
TABLES AVAILABLE ON INVESTOR SITE - http://investors.angiodynamics.com/releasedetail.cfm?ReleaseID=861576.
In the News (Homepage Include)
AngioDynamics, Inc. (ADI) is dedicated to keeping the information you choose to share with us through the web sites (Sites) owned and/or operated by us secure. Ensuring your understanding of how we use and maintain your information is important to ADI. To that end, we have provided below our General Policy and our Registered User Requirements and Information.
- collection and use of information provided by you.
- the privacy protection mechanisms we have implemented; and
- how you can access, update or delete any information provided by you.
I. General Policy.
ADI maintains physical, electronic and procedural safeguards to protect your information. Though no data transmission over the Internet is 100% secure from intrusion, we have used and will continue to use reasonable efforts to ensure the protection of your information. We assess new technology for protecting information and, when appropriate, upgrade our information security systems.
We collect information about you when you visit and use the Sites and when you enter or input information.
You can visit the Sites and learn about our company, products and services, and find out how to contact us without giving us any personal information about yourself. If we request personally identifiable information, you may decline to provide such and thus opt out of receiving future communications from us.
We may use information about you to inform us on how best to update the Sites and enhance the experience for such visitors. Personally identifiable information is not extracted for this purpose. We use such information on an aggregated basis to help us operate the Sites, enhance and improve our service, improve the look of the Sites and display advertising and marketing information. We may use personally identifiable information to display content we think will be of interest to you, or to customize what you see when you visit the Sites.
The information we may collect and store generally consists of information gathered from your registration, data input, forms and other information you provide us, electronically, by phone, in writing, in person or by any other means and information about your transactions and experience with ADI, such as account balances and purchasing activity.
Information is critical to our ability to provide high quality service to you, but the trust that you place in how we provide that service is an important asset. Keeping your information secure is a top priority for all of us at ADI. Consequently, our privacy standards are designed to ensure that we will:
- collect and use only the necessary information required for us to deliver high quality service, to administer our business and to let you know of products and services that are available from our family of companies;
- protect the information you share with us, maintaining strict standards of security and confidentiality;
- not disclose information, personal or business, to any external organization in a manner not otherwise contemplated herein unless we have previously notified you (or the business, in the case of a commercial enterprise) and obtained your consent or if we enter into a specific agreement with you;
- require any other organization that we retain or engage to provide support services for us to conform to our privacy standards.
Your privacy is important to us. However, there are legal and technical reasons why we cannot fully ensure that your personally identifiable information will be kept confidential at all times. For example, we may be compelled to disclose your information to a governmental agency or a court; or third parties may unlawfully intercept or access transmissions or private communications. Additionally, we may (and you hereby authorize us to do so) disclose any information about you to private entities, law enforcement or other government officials as we, in our sole discretion, believe necessary or appropriate to investigate or resolve possible problems or inquiries or to protect our own business and assets. In such circumstances, we will, where possible, require such third parties to maintain the confidentiality of any information so disclosed.
II. Registered User Requirements And Information
Some features on the Sites may require you to register in order to get our authorization before you can use those features. Whether you are an individual or a corporation, partnership or other form of commercial enterprise, in order for you to obtain our authorization to use those features and be considered a registered user, you must provide us with certain information about you and your business and, for security purposes, we may require some personal information about you and, if you represent a business, we may request personal information about those you designate to represent that business.
If you are a registered user, you acknowledge and also consent to our tracking your activities and use of the Sites in connection with the non-public functions of the Sites, such as confirming and filling orders, maintaining quality control and contacting you concerning your orders, transactions or subscription.
In addition to information about your business, for security purposes, we require that you provide us with information such as names, addresses, e-mail addresses, telephone numbers and other personally identifiable information for each individual who will use the Sites, in order for us to authorize you and those individuals to access the features of the Sites that are available only to registered users. This information also helps us to ensure we are able to securely identify you and each of these individuals as authorized users for the features you have successfully registered to use. Once registration is complete and we have granted you authorization, we will provide you with a user identification number and allow you to select a unique user ID and password. You will be able to change your password, as well as any personal data you have given us in order to update your information. If you are a designated representative of a business, keep in mind that an authorized representative of the business will also have the right to revoke that designation and, if so notified, we will immediately terminate your right to use the Sites.
When you submit personally identifiable information on behalf of others, you represent that you have their authorization to provide this information to us. We reserve the right to (i) ask you to provide evidence of that authorization at any time during or after the submission process and (ii) contact those individuals to confirm the authorization. If we determine that such authorization has not been properly obtained, we may immediately and without notice, discontinue your authorization to use the Sites.
Submitting information to us is not a guarantee or assurance that we will grant authorization or permit you, or anyone you designate, to use any or all of the features of the Sites. If, for any reason, you are not granted authorization we will only retain the information you submit to us in order to communicate with you regarding your application and perhaps request additional or follow-up information, for audit purposes or as may be required by law or regulation and we will not use your information for any other purposes.
The personal information you provide and any data, personal or otherwise, that you disclose may be saved on the Sites for the following purposes:
(i) we may use such information to advise you of or provide additional information regarding products or services that may be available through ADI or its affiliates;
(iii) we may disclose such information to third party physicians and health care providers who purchase our products and services for the benefit of their respective patients for the sole purpose of contacting you directly regarding the same, unless you indicate to us via the Site or otherwise in writing that you wish to opt out of such disclosures. Except as set forth above, we do not sell or market your personal information or personalized data to unaffiliated organizations. If you provide us with your email address, we may occasionally send you e-mail and any e-mail sent to us by you through the Sites will be handled and maintained in accordance with the legal and regulatory requirements we must comply with, if any, regarding communications from users and the public.
ADI may collect and use the information you provide to enable us to save you time and money by better understanding your needs so that we can provide you with more relevant information about ADI's products and services.
Some of our Web Sites will send a "cookie," a small text file, to your computer. This allows us to recognize your computer the next time you visit, without bothering you with another request to register. If you do not wish to receive cookies, please refer to the "Help" file of your Internet Browser to learn how to either block all cookies or receive a warning before a cookie is stored. To learn more about cookies we encourage you to visit www.cookiecentral.com If you visit our Web Sites to browse, read, or download information, we collect and store some "visitor information" from you, such as the name of the domain and host from which you access the Internet, the Internet Protocol (IP) address of the computer you are using, the date and time you access our Web Site, and the Internet address of the website from which you linked directly to our Web Site. We use this information to measure the traffic on our Web Sites and to help us make our Web Sites more useful. We delete this information after some time
IV. Information About Minors
V. Links to Other Sites
VI. Anti-Spam Policy
ADI does not distribute or sell customers' confidential information from our opt-in lists.
Definition of Spam from MAPS – Mail Abuse Prevention System
An email is spam if:
- The recipient's personal identity and context are irrelevant because the message is equally applicable to many other potential recipients; AND
- The recipient has not verifiably granted deliberate, explicit, and still-revocable permission for it to be sent; AND
- The transmission and reception of the message appears to the recipient to give a disproportionate benefit to the sender.
- AngioDynamics DOES NOT send out unsolicited email (UCE/Spam) (Please note UCE stands for unsolicited commercial email)
- AngioDynamics DOES NOT knowingly do business with any company that participates in sending UCE/SPAM
- AngioDynamics DOES NOT sell or exchange personal information from our opt-in lists.
Rev. December 16, 2009
A Global Reach, A Community Presence
During the last 25 years, AngioDynamics has grown to have a global reach, with facilities in three U.S. states, The Netherlands, Hong Kong, Germany and Great Britain. The company has its Corporate Headquarters in Albany, N.Y., U.S., and continues to have a major presence in Queensbury, N.Y., U.S., and Glens Falls, N.Y., where it designs, develops and manufactures many of its products. The manufacturing of AngioDynamics’ port systems, electrosurgical devices and needle sets occurs at its Manchester, Ga., U.S., facility, while cutting-edge research and development is performed in Marlborough, Mass., U.S. The company also has opened an International Headquarters in Amsterdam, The Netherlands, and sales offices in Hong Kong and Hamburg, Germany, as well as a facility in Denmead, U.K., focused on the manufacture of its microwave ablation systems.
|New York – Global Headquarters
14 Plaza Drive
Latham, N.Y. 12110 USA
+1 (518) 795-1400
Fax: +1 (518) 795-1401
Airport: Albany International Airport (ALB)
Holiday Inn Express & Suites Latham
400 Old Loudon Road
Latham, NY 12110
(Closest to the Global Headquarters.)
New York – Queensbury Manufacturing Facility
Airport: Albany International (ALB)
Hampton Inn & Suites
New York - Glens Falls Manufacturing Facility
Airport: Albany International (ALB)
25 Lake Avenue
Saratoga Springs, NY 12866
(Within walking distance to restaurants and night life; approximately 30 minutes from facility)
1119 Bullsboro Drive
Newnan, GA 30265
(Closest to restaurants; about 50 miles from facility)
Airport: Logan (BOS)
At AngioDynamics we are focusing on patient care every day, but we understand that undergoing a procedure is not an everyday occurrence for most patients. You probably have a lot of questions, and we hope that the materials on this page will help answer some of the most common questions about our products and your upcoming procedure. Additionally, we have listed links to the Web sites of several organizations below that you may find helpful during your journey. Please remember these are only tools, and that your physician is best suited to answer your questions.
|National Cancer Institute
|American Academy of Dermatology
|American Cancer Society
|American Academy of Family Physicians
|Society of Interventional Radiology
|American College of Phlebology
|American Venous Forum
|Vascular Disease Foundation
To provide benefits to patients by being the leader in design, development, manufacturing and marketing of innovative, proprietary, therapeutic devices used by interventionalists and surgeons for the minimally invasive treatment of peripheral vascular disease, tumor therapy and other, non-vascular disease.
AngioDynamics is deeply committed to improving patient care by ethically serving its customers, shareholders and employees. We value the importance of trust and honesty in all of the relationships that we build. AngioDynamics is dedicated to its pursuit of innovation and tenaciously strives for continuous improvement in every area.
AngioDynamics seeks to add significant value in every interaction with its customers by providing unsurpassed service and the highest quality, best performing products. To accomplish this, AngioDynamics is committed to its employees receiving the highest level of training, and to providing an environment that promotes continual employee growth. All AngioDynamics employees constantly endeavor to be the best and the brightest in the medical device industry.
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics® has grown into a NASDAQ-listed public company with a global reach.
Queensbury was chosen due to its location in the heart of “Catheter Valley,” an area in New York’s Adirondack Region named for its long history of catheter and other medical device manufacturing. Today, the Company has made its presence apparent far beyond Upstate New York with 1,400 employees worldwide at facilities in the United States, Europe and Asia. AngioDynamics is currently selling in more than 50 markets through direct sales and distributors.
Initially dedicated to the research and development of products used in interventional radiology, AngioDynamics began shipping product in the early 1990s. The Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems. In May 2004 the Company became publicly traded on the NASDAQ stock exchange under the symbol ANGO.
Through acquisitions of companies such as RITA Medical Systems in January 2007, Oncobionic in May 2008, and the assets of Diomed in June 2008 and FlowMedica in January 2009, AngioDynamics now boasts a diverse product line that includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products, venous products and targeted renal therapy products.
Continuing its expansion, AngioDynamics opened a new headquarters in Albany, N.Y., in March 2010. Most recently, in May 2012, AngioDynamics acquired Navilyst Medical, bringing market-leading fluid management systems into its portfolio. The acquisition significantly expanded the Company’s scale, doubling its share of the vascular access market while building critical mass in the peripheral vascular market. A comprehensive look at the Company’s history can be found in the form of an interactive timeline of events at www.angiodynamics.com.
|Please be advised, effective January 21st, 2014, AngioDynamics and Navilyst Medical will merge under one unified business information system. This will impact the way our customers order products. All products in the AngioDynamics portfolio will now have universal part numbers. To avoid business interruptions, please visit our resource materials, herein, for further information and updates required.|
14 Plaza Drive
Latham, NY 12110
Hours of Operation:
8 a.m. to 5 p.m. ET
Tel: +1 518-795-1400
Fax: +1 518-795-1401
U.S. Customer Service
Physician Clinical Product Questions
Hong Kong Office
|Investor Relations Contacts
EVC Group, Inc.
Tel: +1 646-445-4801
|Customer Service International
GERMANY/DEUTSCHLAND (08:30 – 17:00 Local)
Rufnummer: 0800 180 8497 (Kostenlos)
Fax: 0800 100 3827 (Kostenlos)
FRANCE (08:30 – 17:00 Local)
Téléphone: 0800 907 948 (numéro Vert - gratuit)
Fax: 0800 940 395 (numéro Vert - gratuit)
NETHERLANDS/NEDERLAND (08:30 – 17:00 Local)
Telefoon: 0800 40 40 013 (Gratis)
Fax: 0800 40 40 014 (Gratis)
UNITED KINGDOM (08:30 – 17:00 Local)
Telephone: 0808 234 7774 (UK Toll Free)
Fax: 0800 358 0866 (UK Toll Free)
ALL OTHER COUNTRIES (08:30 – 17:00 CET)
Telephone: +31 (0) 20 753 2949
Fax: +31 (0) 20 753 2939
I'm now going to add a bunch of new content for the page.